Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
ANI Pharmaceuticals $316.25 million convertible notes offering
We advised ANI Pharmaceuticals on the offering
Penumbra $100 million accelerated share repurchase
We advised Penumbra on the ASR transaction
Walgreens Boots Alliance $750 million notes offering
We advised Walgreens Boots Alliance on its debt offering
CytomX Therapeutics $58.3 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Precigen $34 million follow-on offering
We advised Precigen on the SEC-registered offering
Generation Bio $237 million at-the-market offering
The shares are listed on Nasdaq
Bansk Group $1.5 billion going-private acquisition of PetIQ
We are advising Bansk Group on the transaction
Revolution Medicines $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
AC Immune $80 million at-the-market offering
We advised AC Immune on the offering
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction